Letter

Child influenza vaccination

Panvax febrile reactions not a predictor

BMJ 2010; 341 doi: 10.1136/bmj.c3714 (Published 21 July 2010)
Cite this as: BMJ 2010;341:c3714

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Ruth Lopert, principal medical adviser1,
  2. Terry Nolan, head2
  1. 1Therapeutic Goods Administration, Symonston, ACT 2609, Australia
  2. 2Melbourne School of Population Health, University of Melbourne and Murdoch Children’s Research Institute, Parkville, VIC 3010, Australia
  1. ruth.lopert{at}tga.gov.au

    Collignon and colleagues assert that febrile reactions seen in pandemic influenza A/H1N1 vaccine (Panvax) clinical trials were an overlooked predictor of the excess febrile reactions seen with CSL’s seasonal trivalent influenza vaccine that prompted suspension of its use in children under 5.1 Yet most febrile reactions reported in the Australian Panvax trial were mild, with severe fever (>39.5°C) in only 2%.2 Fever …

    Access to the full text of this article requires a subscription or payment

    Subscribe

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    Rapid responses

    THIS WEEK'S POLL

    BMJ most popular